Discover investment opportunities in Neogenomics Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Neogenomics Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Neogenomics Stocks using our Smart AI Filter.
8 stocks found for "Neogenomics Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.12 | ±24.7% | 13.4 | 0.00% | |||
1.49 | ±53.8% | 37.3 | 375.00% | |||
0.36 | ±20.2% | 16.3 | 1.10% | |||
0.89 | ±41.9% | 22.8 | 0.00% | |||
1.77 | ±71.4% | -18.6 | 0.00% | |||
1.19 | ±53.7% | -156.9 | 0.00% | |||
1.14 | ±68.4% | 37.8 | 0.00% | |||
0.92 | ±45.4% | -143.2 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: How do NEO and NVTA compare in terms of recent growth in the genetic testing sector?
A: NEO (NeoGenomics) and NVTA (Invitae) operate in the genetic testing field, but have different focuses. NeoGenomics specializes in cancer diagnostics, with recent expansions in precision medicine. Invitae offers broad genetic diagnostic services. Both have shown growth, yet investors should examine financial reports for specific growth metrics and projections.
Q: What potential advantages could PACB have over competitors like ILMN in the genomics space?
A: PACB (Pacific Biosciences) offers unique single-molecule, real-time sequencing technology, which could provide accuracy advantages over ILMN (Illumina). However, Illumina's market leadership and established customer base present strong competition. Investors might explore technology differentiation and adoption rates when assessing potential advantages.
Q: Could Fulgent Genetics (FLGT) be considered a stable stock compared to other genomics companies?
A: Fulgent Genetics (FLGT) has shown impressive revenue growth, which might suggest potential stability. However, volatility is common in genomics due to rapid technological advancement and market changes. Comparing FLGT's financial indicators and market movements to others like ILMN and GH can provide more stability insights.
Q: Are there any specific economic cycle considerations for investing in Myriad Genetics (MYGN)?
A: Myriad Genetics (MYGN) operates in predictive and precision medicine, generally less sensitive to economic cycles than cyclical industries. However, R&D expenditures and healthcare regulatory changes could impact profitability. Investors should consider these factors when evaluating MYGN over economic cycles.
Q: How might the shift towards personalized medicine impact Bio-Techne Corporation (BIO)?
A: Bio-Techne Corporation (BIO) is involved in biotechnology tools, essential for personalized medicine. Growth in this area could enhance demand for BIO's products, yet competition and rapid tech changes might influence its market positioning. Consider sector trends and competitive landscape when evaluating BIO's prospects.
Q: Is Guardant Health (GH) appealing for investors focused on early cancer detection technologies?
A: Guardant Health (GH) specializes in liquid biopsy tests for early cancer detection. This niche can attract significant investor interest due to its potential impact on cancer treatment and prognosis. Evaluating GH’s technological advancements and clinical trial outcomes can help determine investment appeal.